Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Beovu shows promise in Real-World eye disease study

NCT ID NCT04543331

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 02, 2026 · Last updated May 24, 2026 · Updated 14 times

Summary

This study looked at how well the drug Beovu (brolucizumab) works in everyday medical practice for people with two eye diseases: wet age-related macular degeneration and diabetic macular edema. Researchers followed 572 patients who were already prescribed Beovu by their doctor, tracking fluid in the eye and vision changes over time. The goal was to see if Beovu helps control these conditions in real-world settings, not just in strict clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97070, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, 37075, Germany

  • Novartis Investigative Site

    Osnabrück, Lower Saxony, 49076, Germany

  • Novartis Investigative Site

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Novartis Investigative Site

    Trier, Rhineland-Palatinate, 54296, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    Schneeberg, Saxony, 08289, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, 06118, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Aschersleben, 06449, Germany

  • Novartis Investigative Site

    Bayreuth, 95445, Germany

  • Novartis Investigative Site

    Berlin, 10713, Germany

  • Novartis Investigative Site

    Berlin, 14163, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Breisach, 79206, Germany

  • Novartis Investigative Site

    Chemnitz, 09113, Germany

  • Novartis Investigative Site

    Cologne, 50968, Germany

  • Novartis Investigative Site

    Dresden, 01067, Germany

  • Novartis Investigative Site

    Dresden, 01324, Germany

  • Novartis Investigative Site

    Esslingen am Neckar, 73728, Germany

  • Novartis Investigative Site

    Glauchau, 08371, Germany

  • Novartis Investigative Site

    Homburg, 66421, Germany

  • Novartis Investigative Site

    Hösbach, 63768, Germany

  • Novartis Investigative Site

    Kiel, 24103, Germany

  • Novartis Investigative Site

    Leipzig, 04106, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    Marienberg, 09496, Germany

  • Novartis Investigative Site

    Münster, 48145, Germany

  • Novartis Investigative Site

    Neubrandenburg, 17036, Germany

  • Novartis Investigative Site

    Neuburg am Inn, 86633, Germany

  • Novartis Investigative Site

    Saarbrücken, 66111, Germany

  • Novartis Investigative Site

    Schönebeck, 39218, Germany

  • Novartis Investigative Site

    Stralsund, 18435, Germany

  • Novartis Investigative Site

    Sulzbach, 66280, Germany

  • Novartis Investigative Site

    Torgau, 04860, Germany

  • Novartis Investigative Site

    Waren, 17192, Germany

  • Novartis Investigative Site

    Würzburg, 97080, Germany

Conditions

Explore the condition pages connected to this study.

DIABETIC MACULAR EDEMA (DME) NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)